Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis

Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Takeshi Yuasa Shinji Urakami Shinya Yamamoto Junji Yonese Kazutaka Saito Shunji Takahashi Kiyohiko Hatake Iwao Fukui
  • چاپ و سال / کشور: 2011

Description

We retrospectively analyzed treatment outcomes and factors for poor prognosis for patients with renal cell cancer (RCC) bonemetastases. Patients with bone metastases at initial diagnosis ofmetastasis secondary fromRCC, treated at our hospital between 1984 and 2009, were retrospectively reviewed and statistically analyzed.Among 214RCCpatients with metastasis, 71 patients (33%) were found to have bone metastases at initial diagnosis of metastasis. The median follow-up was 21.1 months (intra-quartile range: IQR, 9.1–47.4 months). The estimated median overall survival time from the diagnosis of bone metastasis was 27.7 months. The probability of patients surviving at 1, 2, and 5 years was 63.7, 52.2, and 19.3%, respectively.When they were stratified by MSKCC scores, the probability of the median overall survival of the populations classified as favorable, intermediate, and poor was not reached, 32.9, and 10.5 months, respectively (P = 0.002). In addition, poor performance status (PS) (hazard ratio [HR]: 1.938, P = 0.035) and no prior nephrectomy (HR: 3.008, P = 0.004) were extracted as independent poor prognostic factors by multivariate analysis. All treatment modalities—including radical en bloc surgery, radiation therapy, cytokine therapy, molecular targeted therapy, and administration of zoledronic acid—seemed to contribute to favorable survival. More than half of the patients with bone metastases secondary from RCC were predicted to survive more than 24 months. In this population, MSKCC scores were valid predictors of survival. With increased treatment options, RCC patients with bone metastasis may benefit further from subsequent modalities and/or agents.
Clin Exp Metastasis (2011) 28:405–411 DOI 10.1007/s10585-011-9379-7 Received: 21 September 2010 / Accepted: 15 February 2011 / Published online: 3 March 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری